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Abstract
Subjects: Twenty vertically HIV-infected children, 6–16 years of age, with stable viral load control and CD4+ values above
400 cells/mm3.
Intervention: Ten subjects continued their ongoing antiretroviral treatment (ART, Group A) and 10 were immunized with a
HIV-DNA vaccine in addition to their previous therapy (ART and vaccine, Group B). The genetic vaccine represented HIV-1
subtypes A, B and C, encoded Env, Rev, Gag and RT and had no additional adjuvant. Immunizations took place at weeks 0, 4
and 12, with a boosting dose at week 36. Monitoring was performed until week 60 and extended to week 96.
Results: Safety data showed good tolerance of the vaccine. Adherence to ART remained high and persistent during the
study and did not differ significantly between controls and vaccinees. Neither group experienced either virological failure or
a decline of CD4+ counts from baseline. Higher HIV-specific cellular immune responses were noted transiently to Gag but
not to other components of the vaccine. Lymphoproliferative responses to a virion antigen HIV-1 MN were higher in the
vaccinees than in the controls (p = 0.047), whereas differences in reactivity to clade-specific Gag p24, RT or Env did not reach
significance. Compared to baseline, the percentage of HIV-specific CD8+ lymphocytes releasing perforin in the Group B was
higher after the vaccination schedule had been completed (p = 0.031). No increased CD8+ perforin levels were observed in
control Group A.
Conclusions: The present study demonstrates the feasibility, safety and moderate immunogenicity of genetic vaccination in
vertically HIV-infected children, paving the way for amplified immunotherapeutic approaches in the pediatric population.
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Introduction
Current antiretroviral therapy (ART) recommended for the
HIV-infected pediatric population requires medication early, daily
and indefinitely [1]. The life-long need for strict adherence and the
costs of chronic treatment encourage the exploration of alternative
approaches that could potentially be complementary to long-term
management of pediatric HIV infection. Young children who are
highly adherent to ART frequently encounter adherence problems
during adolescence [1]. Recent data clearly show that vertically
HIV-infected children have a progressively increased risk of
developing triple-class virological failure after 5 years on highly
active ART [2]. Thus, new therapeutic strategies are necessary for
the pediatric population, particularly as these children approach
adolescence. Transient decay of latently HIV-infected CD4+ T-
cells has been reported after a therapeutic vaccination with a HIV-
recombinant poxvirus [3]. Furthermore, T-cell induced HIV viral
modifications have been reported with an adenovirus-based
prophylactic HIV vaccine in the STEP trial [4]. These data
demonstrate the possibility of exerting selective viral pressure with
a vaccine strategy. However, no data on immunotherapeutic HIV
vaccine strategies are yet available for children. Here we report
data from the PEDVAC trial, which is the first study of an HIV-
DNA therapeutic vaccine in vertically infected children.
Materials and Methods
Study subjects and trial design
The PEDVAC trial is a single center, phase II open label
randomized trial, laboratory blinded, which evaluates feasibility,
safety and immunogenicity of a multiclade, multigene HIV-DNA
vaccine (HIVIS) [5]. The trial was judged as a phase IIa trial by
the Italian regulatory Agencies (AIFA) according to the definition
by the National Institutes of Health, Bethesda, USA: ‘‘pilot, proof of
concept clinical trials to evaluate efficacy (and safety) in selected populations of
patients’’ [6]. HIV vertically infected children (4–16 years of age),
on stable antiretroviral regimen for at least 6 months with HIV-
RNA,50 copies/ml and stable CD4+ counts ($400 cells/mm3 or
25%) over 12 months of follow-up, were eligible for the study.
Patients with ongoing other infections or on treatment with
immunomodulatory agents or with signs or history of autoimmune
diseases were excluded from the study. Between January and
September 2009, 25 vertically HIV-infected children were
screened for this study, 20 of whom were enrolled: 10 in each of
Groups A and B (Figure 1). Enrolled patients were randomized at
week 22 into two groups: a control group of 10 children who
continued previous antiretroviral regimen (control Group A) and a
group of 10 children immunized intramuscularly with the HIV-
DNA vaccine, in addition to their previous and ongoing
antiretroviral regimen (vaccine Group B). Clinical and laboratory
evaluations were performed at baseline (weeks 22 and 0) and at
weeks 4, 12, 16, 20, 36, 40, 48, 60, 72, 84 and 96. In addition,
HIV viral load, lymphocyte subsets, anti-ANA and anti-dsDNA
antibodies were performed at each time point [5]. Immunizations
by intramuscular injection were scheduled at weeks 0, 4 and 12,
with a boosting dose at week 36. All vaccine doses were
administered at the Clinical Trial Center Unit, ‘‘Bambino Gesu`’’
Children’s Hospital, Rome, Italy. ART was continued in all
patients during the immunization schedule and for the duration of
the study. The protocol for this trial and supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocol S1.
Ethical approval
The trial Eudract number 2007-002359-18 was approved by
the Ethical Committee of the Children’s Hospital ‘‘Bambino
Gesu`’’ and by the Italian Regulatory Agency for Drug Adminis-
tration (AIFA), and conducted in accordance with the Declaration
of Helsinki. Written informed consent was approved by the Ethical
Committee of the hospital and obtained from all participants and
from their guardians. All the source documents, including each
patient’s case report form (CRF), have been stored in a locked
secure area at the Clinical Trial Center of the hospital.
Randomization and blinding
The randomization schedule was prepared by the statisticians at
the Clinical Trial Center of ‘‘Bambino Gesu`’’ in Rome. The
randomization list was performed by Electronic Software available
at RANDOM.ORG. Laboratory staff remained blinded with
respect to the allocation of control or vaccine group.
Vaccine and formulation
Two preparations of HIV-DNA plasmids have been prepared
for the HIVIS vaccine: (1) DNA plasmids (2 mg/ml) encoding
HIV Env A, B, C and Rev B [Ampoule 1, 0.7 ml pKCMV (rev, envA,
envB, envC)]; (2) DNA plasmids (2 mg/ml) encoding HIV Gag A, B
and RT mut B [Ampoule 2, 0.5 ml pKCMV (gagA, gagB, RTmut)]. In
vitro each plasmid expresses 10–100 fg protein/transfected cell
when delivered separately, in vivo in mice electroporation or Bioject
delivery enhances immunogenicity around 100-fold [8,9,10].The
vaccine was manufactured in accordance with Good Manufac-
turing Practice by Vecura (Karolinska Institutet and University
Hospital at Huddinge, Stockholm, Sweden). It was approved by
the Medical Products Agency (La¨kemedelsverket) for a prophy-
lactic HIV vaccine study of 40 healthy adults in Sweden [7,8] and
by the Italian Regulatory Agency for Drug Administration (AIFA)
for the present study. The vaccine was not adjuvanted following
results obtained in healthy adult volunteers, where higher cellular
responses were detected without the administration of granulocyte
macrophage colony stimulating factor (GM-CSF) as adjuvant [7].
Each child received 4 ampoules at each vaccination visit (2 of
ampoule no. 1 in the right arm and 2 of ampoule no. 2 in the left
arm), amounting to a total of 3.8 mg DNA, by intramuscular
injection in the two deltoid sites. Division of plasmids into two lots
was done to avoid immunodominance of either composition [9].
Safety evaluation
Physical and laboratory safety evaluations were performed as
previously described [5]. All medical events were recorded as
possible adverse events and were graded by the principal
investigator as to their severity and relationship to the immuni-
zation. Immediate local (erythema, induration, pain, regional
lymphadenopathy, restricted movement) and systemic (headache,
nausea, fatigue, fever, gastrointestinal upset, vomiting, diarrhoea,
myalgia, hypersensitivity) reactions were directly observed during
the first hour after the HIV-DNA application. HIV-infected
children or their parents recorded in a self-administered diary card
the occurrence and severity of solicited local and systemic events,
using a standard scale to grade reactions [5].
Lymphoproliferation assay (LPA)
Fresh peripheral blood mononuclear cells (PBMC) were
analyzed by lymphoproliferation assay as previously described
[5,11]. Briefly, 26105 PBMC were cultured in 96 well plates for 7
days with the following antigens: aldrithiol-2 (AT-2)-treated HIV-1
MN virions subtype B at 2.5 mg/ml and non-viral control antigen
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SUPT1 microvesicles at 2.5 mg/ml (kindly provided by Dr. J.
Lifson, SAIC Frederick, Inc., Frederick, USA) recombinant
proteins rgp160 at 0.5 mg/ml (Protein Sciences, Meriden, CT,
USA), Reverse Transcriptase (rRT) subtype B at 0.5 mg/ml, rgp41
at 0.5 mg/ml, rp24 0.5 at mg/ml, and recall antigens Cytomeg-
alovirus (CMV) at 0.5 mg/ml and Candida Albicans at 0.5 mg/ml
(Nanogen TO, IT). Results are shown as mean values of duplicates
and are expressed as counts per minute (cpm). Stimulation index
(SI) was defined as previously described [5,11]. SI was considered
as positive when $3. For stimulation by HIV-1 MN inactivated
virions, the cut off was set at SI 15, since lymphocytes from non-
infected controls at times reacted with both the SUP T1 control
and HIV-1 MN preparations.
Intracellular cytokine staining assay
Heparinized fresh whole blood (100 ml) diluted 1:2 in complete
RPMI medium was incubated with 1 mg each of anti-CD28 and
anti-CD49d monoclonal antibodies (mabs) and 1 mg of a protein
pool consisting of recombinantly produced proteins representing
the vaccine sequences HIV-1 RT (Clade B), HIV-1 p17/24 (Clade
B), HIV-1 p17/24 (Clade C), HIV-1 UG37 gp140 (Clade A) and
CN54 gp140 (Clade C) or controls (anti-CD49d and anti-CD28
mabs) for 16 h. After 2 h, brefeldin A (Sigma-Aldrich, St. Louis,
MO) was added, 10 mg/ml. After 14 h, cells transferred to 5 ml
tubes were stained with anti-CD3, anti-CD4 and anti-CD8
antibodies. Red blood cells were lysed with BD FACS Lysing
solution (BD, San Jose`, CA), fixed with 4% paraformaldehyde and
washed with PBS with 1% bovine serum albumin (BSA).
Lymphocytes were stained with anti IFN-c mab in PBS with 1%
BSA and 0.5% saponin. Cells resuspended in Facs Flow were
analyzed with a FacsCanto II. Data files were analyzed using
DIVA software (BD) and results expressed as percentage of
cytokine-producing CD3+, CD4+ and CD8+ T-cells. Results were
considered positive when the percentage of cytokine-secreting cells
Figure 1. CONSORT 2010 flow diagram.
doi:10.1371/journal.pone.0079957.g001
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of HIV-stimulated cultures was higher or equal to 0.02% above
unstimulated cultures and were considered assessable if the
percentage of cytokine-producing control cells was lower than
0.06% [5,12].
TZMbl neutralization assays and preparation of
pseudoviruses
Pseudovirus (PSV) of HIV-1 strain SF162 was prepared by
transfection of 293T cells as previously described [13]. To
circumvent the effect of reverse transcriptase (RT) inhibitors
present in sera, we utilized an RT-resistant backbone vector,
1617RT/K103N, which carries mutations in the pol gene
conferring resistance to nucleoside and non-nucleoside reverse
transcriptase inhibitors. SF162 PSV-1617RT/K103N tested with
antiretroviral drugs Efavirenz, NVP, Zidovudine, Saquinavir and
Raltegravir, showed that Efavirenz and Raltegravir were the only
drugs still interfering in the TZMbl assay. To further exclude
unspecific inhibiting effects, sera were also tested against the
vesicular stomatitis (VSV) pseudovirus. The PSVs and TZMbl
neutralization assays were performed with a previously described
protocol using four steps of 4-fold dilutions starting with 1:20 of
each serum [14].
Plasma HIV-RNA determination
Plasma HIV-RNA was determined using a quantitative b-DNA
assay (Quantiplex HIVRNA 2.0 bDNA Assay, Chiron Diagnostics
Corporation, Emerville, CA, USA) with a lower limit quantifica-
tion of 50 copies/ml of plasma.
Quantification of residual plasma HIV-RNA viremia
Plasma obtained from blood sampled in EDTA was stored
frozen at 280uC until tested. Residual viremia was quantified by
an ultrasensitive assay, based on Amplicor HIV-1 Monitor v1.5
(Roche Molecular Systems, USA) with a limit of detection of 1
copy/ml. Modifications include pelleting of the virus from 2 ml or
more of plasma at 200.000 g at 4uC for 1 h. The HIV-RNA pellet
is extracted by adding half of the normal volume of quantification
standard, suspended in 1/8 of standard volume diluents, and
assayed by reverse transcription and polymerase chain reaction
(PCR). PCR and detection steps follow the manufacturer’s
protocol. To calculate HIV-RNA copy number, we adjusted the
correction factor according to the modified volume of the internal
quantification standard.
Cell-Associated HIV-DNA quantification
Total cell DNA is extracted from PBMC pellets with High Pure
PCR Template Preparation Kit (Roche Molecular Biochemicals,
Germany) and stored at 220uC. Total HIV-DNA is quantified by
real-time polymerase chain reaction, using 59 nuclease assay in the
long terminal repeat (LTR) region of proviral HIV-1 (reference
sequence HXB2) performed on a LightCycler v3.5 (Roche
Molecular Biochemicals, Indianapolis, IN). Up to 500 ng of
DNA is amplified with sense primer NEC 152 and reverse primer
NEC 131, producing a 121 bp fragment in the presence of a
dually (FAM and TAMRA) labelled NEC LTR probe [15,16] and
read on channel F1/F2 of the Light Cycler. The PCR sensitivity
was 1 copy of HIV-DNA/reaction (approximately equal to 10
copies/106 PBMC’s of total HIV proviral DNA). To verify DNA
integrity we used LC control DNA Kit reagents (Roche Molecular
Biochemicals, Germany) to amplify a 110 bp fragment of human
b-globin in the same reaction. This internal control target
hybridises with a FRET probe and is read on channel F3/F2.
To verify the accuracy of the Real-Time PCR result, different
HIV-1 DNA standards were also quantified [17]. Results are
expressed as number of total HIV-proviral DNA copies/106
PBMC.
Psychological impact of the PEDVAC trial
Difficulties in being part of a therapeutic vaccine trial and its
impact on adherence to treatment were assessed from week 0
onwards by a specifically developed questionnaire adapted from
WHOQOL-HIV and PENTA (Pediatric European Network for
Treatment of AIDS), as previously described [12]. Before study
entry, the aim of the study was extensively explained to the eligible
patients and their parents by the personal physicians and a
psychologist. Questionnaires were filled in at the time of scheduled
visits to the clinic by parents or caregivers and patients with the
help of a medical psychologist.
Statistical analysis
The present study was intended as an exploratory proof of
concept to test feasibility and immunogenicity of therapeutic DNA
vaccination in vertically HIV infected children. With currently
available antiretroviral regimes, there are good possibilities to
prevent mother-to-child viral transmission when the HIV infection
of the mother is known. Consequently there is a low incidence of
vertical HIV infection in children where treatment of mother and
newborn is available. Therefore, we had a limited number of
children with vertical HIV infection available. For practical
reasons and in concert with the ethical committee of the
Children’s Hospital ‘‘Bambino Gesu`’’ we chose to recruit 20
children to randomize to receive DNA vaccine or to serve as
controls, both groups receiving standard antiretroviral treatment.
Study data were entered under study code and initials on clinical
report forms. Clinical and vaccine safety laboratory data were
entered in an Access (Microsoft) database. Statistical calculations
were performed in IBM SPSS Statistics, version 19 (SPSS, Inc.)
and GraphPad Prism Software version 5.00. Statistical significance
was accepted if p#0.05. As regards calculations on the immuno-
logical outcome measures, the area under the curve (AUC)
methodology of responses for the whole follow up period were
chosen as a summary measure as suggested by Matthews et al (18).
AUC was chosen because the biological responses to HIV were of
peaked manner and there were unequal time intervals between
testing. As regards cellular immune reactivity from lymphocyte
proliferations, intracellular assays and HIV-RNA viral load values
(including ultrasensitive HIV-RNA), AUC [18] were calculated
from baseline to week 96 for each patient and potential differences
between the vaccinated and control groups were analysed by
independent samples t-test. With this selected approach, we had
power to detect only larger magnitudes of between group
differences as regards the AUC summary measures of immune
responses. With 10 subjects in each group, an effect size of 1.32
was needed for a power of 0.8 to detect a statistically significant
difference between the groups by t-test, this transfers to a critical t
of 2.1 with the variance of the existing data, this means for
example a mean difference of over 278 SI for the mean MN data
and a mean difference of over 46 SI for the RT data. The within
group difference in the intracellular staining assays at weeks 0 vs
60 was analyzed by Wilcoxon signed-rank test for the vaccinated
and control groups respectively. Differences in rate of adherence
during the study were calculated by significance test for a
difference in two proportions [19]. Comparison between the
vaccinated and control groups for HIV-DNA values was
calculated by Mann-Whitney U test. The relationship of HIV
antigens p24 and HIV-MN reactivity was calculated by Spear-
man’s rank correlation on samples at week 16.
Therapeutic Vaccination of HIV-Infected Children
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Results
Patients enrolled
Five patients withdrew after viewing the follow-up flowchart
(Figure 1). Failures during screening were due to the lack of
consent to planned additional visits. Baseline characteristics of 20
enrolled children are reported in Table 1. All patients were long-
term virally suppressed before study entry, vaccinees during a
median of 69 months (range 12–137) and the controls for a median
of 101 months (range 13–156). Median time and range of
Table 1. Patient data at enrolment.
GROUP A Controls GROUP B Vaccinees
Female/Male 6/4 6/4
Age (years) median (range) 12,0 (8,1–16,3) 11,5 (6,3–14,3)
CD4+ percentage median (range) 35,5 (28–47) 34 (28–42)
CD4+ no. of cells/mm3, median (range) 748,5 (423–1188) 798 (497–1094)
Median time in months with HIV,50 copies/ml before study entry
(range)
101 (13–156) 69 (12–137)
ART: 2 NRTI/PI 5/10 4/10
ART: 2 NRTI/NNRTI 5/10 6/10
Median time in months with the same ART (range) 12 (12–42) 16,5 (9–46)
Early ART treated children within the first year of life 2/10 2/10
ART signifies antiretroviral treatment with PI = protease inhibitors, NRTI = nucleoside reverse transcriptase inhibitors, NNRTI = non nucleoside reverse transcriptase
inhibitors.
doi:10.1371/journal.pone.0079957.t001
Figure 2. Safety Profile of the PEDVAC trial: distribution of adverse events during the 96 weeks follow-up of the study. The black
dashed line shows total number of solicited and unsolicited adverse events in control Group A. The gray dashed line indicates total number of
solicited and unsolicited adverse events in vaccine Group B, while the black solid line indicates all local and systemic adverse events which were
vaccine related. Black arrows show vaccinations (weeks 0, 4, 12 and 36).
doi:10.1371/journal.pone.0079957.g002
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treatment with the same ART regimen is also reported in Table 1.
Four enrolled patients were treated early with ART (within the
first year of life) and were equally randomized to the two groups.
All 10 patients in Group B completed the vaccination schedule.
Vaccine safety
The vaccine and the vaccination procedures were safe and well
tolerated. A total of 130 solicited and unsolicited adverse events
were recorded, 73 were reported by the vaccinees and 57 by the
control group. The distribution of the frequency of adverse events
was similar in control Group A and vaccine Group B, with the
highest frequency following the first vaccination (Figure 2). All
reactions were generally self-limiting, resolving within a 72-hour
period. No grade 3 or 4 events occurred and no accumulation of
adverse events leading to discontinuation of the vaccination was
registered. An overall of 68 solicited adverse events were recorded
during the vaccination schedule in both groups (46 in vaccine
Group B and 22 in control Group A). In vaccine Group B, 38 of
46 events were judged as related to the vaccination, 24 systemic
and 14 local events. Local events were described as itching,
swelling and pain at the injection site. Two out of these 14 local
events were graded as moderate and recovered with Paracethamol
Figure 3. Viral dynamics during the vaccination schedule for the control Group A (n=10) (A) and vaccine Group B (n=10) (B). HIV-
RNA with a limit of detection of 50 copies/ml is shown as black dots, HIV-RNA ultrasensitive assay with a limit of detection of 1 copy/ml plasma is
shown as circles and cell associated HIV-DNA of PBMC shown as triangles indicating number of total HIV-proviral DNA copies/106 PBMC. Black arrows
show vaccinations (weeks 0, 4, 12 and 36).
doi:10.1371/journal.pone.0079957.g003
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therapy: a swelling reaction larger than 3 cm and an onset of
moderate pain (grade 2) at the vaccine injection site. In control
Group A all 22 solicited adverse events were systemic and self-
limiting. An overall of 62 unsolicited adverse events (27 in vaccine
Group B and 35 in control Group A) were collected and
considered not related to the vaccination. Vaccinations did not
influence biochemical parameters. None of the volunteers
developed anti-double-stranded anti-DNA antibodies at any time
point throughout the study. CD4+ T-cell counts remained stable
during the study period.
Adherence to antiretroviral therapy did not significantly change
during the study follow-up. Self-reported adherence to ART
temporarily decreased, from 100% in both groups at baseline to
80% (2 out of 10) in the vaccinees and to 90% (1 out of 10) in the
control group at week 60 (p.0,5). Periods of poor adherence to the
antiretroviral regimen were decided by the patients and did not
exceed a mean of 3.7 days (SD 2.3) in the control Group A vs 5.5
days (SD 1.6) in the vaccine Group B, as reported in the diaries. All
patients in both groups reported that they were fully adherent to the
treatment at the following week. No virological failure leading to
switching of the antiretroviral regimen was observed (Table 1).
Virological outcome
No patient experienced virological failure. Three children (one
in the control Group A, two in vaccine Group B) experienced a
single viral blip of plasma HIV-RNA, which returned to under 50
copies/ml of viral RNA at the following determination. None of
those three blips exceeded 1000 copies/ml of HIV-RNA, as
verified also by ultrasensitive HIV-RNA determinations (Figure 3).
The median cellular proviral DNA load remained stable between
baseline and week 48 in both groups; control Group A: 259
copies/106 PBMC (range 13–1290) vs 452 copies/106 PBMC
(range 66–2899); vaccine Group B: 552 copies/106 PBMC (range
40–1396) vs 698 copies/106 PBMC (range 93–1330). No
significant differences between the two groups were observed by
ultrasensitive HIV-RNA plasma viral load assays at baseline,
weeks 16 and 40 or by cell-associated HIV-DNA assays at weeks 0
and 48 (Figure 3).
Immunogenicity
We found a statistically significant difference between the
groups as regards cellular immune responses estimated as
stimulation index (SI) by the virion antigen HIV-1 MN as
calculated by the area under the curve (AUC) values [18]. Figure 4
illustrates the lymphoproliferative responses to antigens HIV-1
MN, HIV p24 Gag and HIV RT, the two latter with trends to
significance (Table 2). No differences were observed between the
two groups regarding specific lymphoproliferative responses to
antigens representing HIV Env, such as gp41 or gp160, or control
CMV and Candida antigens.
Figure 4. Lymphoproliferative responses are shown as Stimulation Index (SI) to virion HIV-1 MN (A), recombinant Gag p24 (B) and
recombinant RT (C) viral antigens among vaccinated (n=10; black dots and lines) and controls (n =10; grey squares and lines). Black
arrows show vaccinations (weeks 0, 4, 12 and 36).
doi:10.1371/journal.pone.0079957.g004
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It can be noted that the HIV-1 MN virion antigen is thought to
mainly stimulate anti-Gag reactivities. The ranked reactivities to
the HIV-1 MN and Gag p24 antigens for week 16 samples,
showed a correlation of r = 0.50 (p = 0.03, Spearman’s test). From
this we assumed that anti-Gag reactivities were the principle
immune reactivities detected in the vaccinated Group B individ-
uals.
The functional profile of HIV-specific CD4+ and CD8+ T-cells
was then analyzed by intracellular cytokine staining (ICS) at weeks
0, 16, 20 and 60. T-cell functions were analysed by pools of
proteins representing the vaccine sequences. The panel of T-cell
functions analyzed included IL-2, IFN-c and perforin production
and release for both CD4+ and CD8+ T-cells (Figure 5). IFN-c
positive CD8+ lymphocytes, as well as IFN-c positive or IL-2-
positive CD4+ lymphocytes, did not differ significantly between
the two groups (Figure 5 panels A–D). Table 2 summarizes p-
values calculated by the AUC method for ICS determinations.
Compared to baseline, the percentage of HIV-specific CD8+
lymphocytes releasing perforin in the vaccinated Group B was
higher after the vaccination schedule had been completed
(p = 0.031). No such increase was observed in control Group A
(Figure 5 panel E).
Neutralizing antibody responses were determined in the TZMbl
assay against HIV-1 strain SF162 expressed in the RT-resistant
backbone 1617RT/K103N, due to the fact that the children were
ART treated. Despite the modified PSV backbone, interference
due to Efavirenz allowed antibody determination only for 9
children, 5 not vaccinated and 4 vaccinated. Independently of the
group, most children had neutralizing antibody at baseline (ID50
titers ranging from 87 to 1007), which remained stable or had
dropped slightly at 40 weeks of follow-up (ID50 titres ranging from
27 to 596). Thus, the vaccination protocol did not appear to affect
antibody levels.
Psychological impact of the PEDVAC trial
A total of 200 questionnaires covering the whole period were
analyzed by the clinical psychologist after the 96 week follow-up
visit. The reported quality of life was high in both groups and
showed no variations during the study period. At study entry, a
majority of the patients and their parents (80%) who enrolled in
the vaccine group had high expectations of the trial. The
possibility of being cured and discontinuing the daily intake of
drugs were the main hopes reported by the vaccinees. A majority
(60%) in the control group of patients wished they had been
selected for the vaccine group. Comprehension of the study aims
increased over time in both groups.
Discussion
The present trial demonstrates, for the first time, the feasibility,
safety and moderate immunogenicity of an HIV-DNA therapeutic
vaccine in vertically HIV-infected children. While interpretations
should be tempered by the relatively small study size and by the
study design (HIV-DNA as both prime and boost and no
withdrawal design), there are a number of significant observations
that merit additional investigation.
First, HIV-DNA vaccination is a feasible and safe strategy in the
pediatric population. No major adverse events were reported by
the vaccine schedule. We saw no indication of increased viral load
caused by vaccination. Importantly, genetic vaccination was not
observed to increase the size of the viral reservoir [20]. Overall,
these data confirm the safety profile of genetic vaccination
reported in healthy and HIV-infected adults with the same
HIV-DNA vaccine, HIVIS [7,21,22]
Second, genetic immunization in the context of ART is a
feasible strategy since it does not negatively impact quality of life,
adherence to antiretroviral drugs or viral control. In the present
study, viral load was stably suppressed in both vaccinees and
controls. This can be the direct result of the high adherence to
ART reported in this study, due to the fact that enrolment in
Table 2. Cellular immune responses to HIV-1 antigens.
AUC SIa, mean (SD)
Antigen Vaccinated Controls p
HIV-1 MN 757.7 (387.0) 456.4 (157.6) 0.047
p24 226.7 (123.7) 148.9 (37.6) 0.073
RT 163.5 (57.1) 121.9 (39.8) 0.075
rGP160 170.6 (69.0) 125.7 (23.6) 0.067
Gp41 142.5 (40.6) 125.7 (23.6) 0.414
Candida 656.3 (352.9) 860.5 (616.5) 0.375
Cytomegalovirus 808.1 (904.2) 748.0 (629.6) 0.865
AUC of the percentage of CD3+CD4+ or CD3+CD8+ cells producing IL2 or IFN-gamma or releasing perforin, mean (SD).
Cytokines Vaccinated Controls p
CD8+ perforin 30.5 (35.8) 11.7 (11.7) 0.132
CD8+ IFN- c 2.1 (3.7) 0.7 (0.6) 0.246
CD4+ IL-2 2.0 (1.8) 2.3 (2.3) 0.764
CD4+ IFN- c 1.1 (0.7) 0.9 (0.4) 0.401
CD4+ IL-2 and IFN- c 0.3 (0.3) 0.3 (0.5) 0.824
AUCarea under the curve.
aweek 0–96.
bweek 0–60.
doi:10.1371/journal.pone.0079957.t002
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Figure 5. Functional profiles of between groups HIV-specific CD4+ and CD8+ T-cells analyzed by ICS at weeks 0, 16, 20 and 60. The
panels show the percentage of T-cells releasing IFN-c (A) and IL-2 (B) for CD4+ T-cells, and IFN-c (C) and perforin (D) for CD8+ T-cells for each patient
in control Group A (n = 10, circles), and vaccine Group B (n = 10, black dots). T-cell functions were analyzed after stimulation for 16 h with a pool of
proteins representing the vaccine sequences. Lines represent median values. In panel (E) CD8+ cells releasing perforin at baseline week 0 and after 60
weeks in vaccine and control groups are shown. Differences within groups between baseline and week 60 levels in panel (E) are indicated for each
individual, and the p-value calculated by Wilcoxon signed rank test.
doi:10.1371/journal.pone.0079957.g005
Therapeutic Vaccination of HIV-Infected Children
PLOS ONE | www.plosone.org 9 November 2013 | Volume 8 | Issue 11 | e79957
clinical trials increases the medication compliance and virological
control [23,24].
Third, HIV-DNA vaccination of vertically HIV-infected
children, who were receiving durable effective ART, was
associated with a moderate and transient appearance of HIV-1
MN (Gag) and trend to RT-specific lymphoproliferative responses.
Gag specific T-cell responses have been shown to correlate with
lower levels of viral load in chronically infected patients
[4,25,26,27], and with a better prognosis [28,29]. Similarly, RT
specific T-cell responses have been reported to be of protective
value in HIV-infected individuals [30,31]. Increased anti-RT
cellular reactivities were transiently discovered in a few of the
vaccinated children. This is interesting, since in healthy and
infected adults vaccinated with the same vaccine, anti-RT
responses were measurable in a minority of individuals. Some
infected children thus might be more able to react with viral rRT
proteins than infected adults, probably as a reflection of a more
intact immunological status [29]. The absence of a T-cell
activating adjuvant and the low endogenous antigenic stimulation
due to the long-term viral suppression during the entire study is
consistent with the transient and mild increase of HIV-specific
lymphoproliferative immune responses observed in the present
trial.
Furthermore, a significant increase in the frequency of HIV-
specific CD8+ lymphocytes releasing perforin was observed after
HIV-DNA vaccination at week 60 when compared to baseline
values. However, we cannot distinguish if these effects result from
the induction of true de novo responses or derive from preexisting
antigen-experienced T-cell responses. In HIV-infected children
with complete viral suppression, the HIV-specific CD8+ cellular
responses decrease below detection, showing that active viral
replication is required to maintain such responses at detectable
levels [32]. The observation that the majority of the HIV-specific
CD8+ cellular responses at baseline in our study were below
detection is in line with these data. Therefore, the persistently low
virological burden observed in our cohort suggests that the HIV-
DNA vaccination can increase the frequency of CD8+ lympho-
cytes releasing perforin. However, it is likely according to previous
data in vertically HIV-infected children [32], that these cells do
not remain fully functional in the absence of the continued
antigenic stimulation provided by vaccination or transient viremia.
Fourth, boosting vaccination with HIV-DNA after HIV-DNA
priming was not a fully effective strategy. The HIV-DNA vaccine
contains full genetic information for Gag, RT and Env proteins,
together representing subtypes HIV-1 A, B and C. This
theoretically best covers both the viral variation and the many
polymorphic genes/gene products of HLA classes I and II alleles,
but perhaps at the cost of strong peptide-focussed responses. A
heterogeneous approach in which the boost consisted of recom-
binant vaccinia- or adeno-based HIV genes has led to broad and
strong cellular immunities followed by antibody induction in
healthy adults [7,22,33,34,35]. A DNA vaccine carrying CpG
sequences that engage Toll-like receptor 9 (TLR 9), which in turn
redirects the immune response from Th2 to Th1 reactivity [36],
can be another feasible and innovative strategy to enhance cellular
immunogenicity of DNA vaccines. Other new experimental
strategies, as in vivo electroporation or cytokine genes, might
enhance the potency of DNA immunizations to match immune
responses induced by heterologous prime-boost immunizations
[10,37]. It was however not possible to design similar prime-boost
or experimental immunization schedules in the childhood
population without prior demonstration of safety of genetic HIV
vaccination. The fact that no novel neutralizing antibody
responses were elicited is disappointing, but consistent with the
performance of other stand-alone DNA vaccines delivered to date
[37].
Overall, our data pave the way to explore immunotherapeutic
approaches in the pediatric HIV population, particularly aiming at
increasing the strength and durability of anti-viral responses. The
role of HIV therapeutic vaccines in childhood is debated due to
the efficacy of antiretroviral therapy in maintaining long-term
virus suppression. Antiviral therapy and therapeutic vaccination
have mostly been perceived as alternative intervention strategies,
particularly by the patients and their families. The major goal of a
therapeutic vaccination thus far, has been the induction of cellular
immune responses that control viral replication, thus allowing the
interruption of antiretroviral therapy. However, it is unrealistic to
think that therapeutic vaccination will stimulate HIV-specific T-
cell responses to achieve full and persistent HIV-viral suppression
as efficiently as a combination of antiretroviral therapies.
Therapeutic vaccination thus should target those patients who
present high risk factors to develop virological failure and viral
resistant strains, with the final aim to reduce viral rebound in less
adherent patients. The largest pediatric epidemiological study in
Europe recently reported that 12% of HIV infected children had
triple-class virological failure after 5 years on ART, and about a
fifth had such treatment failure by 8 years on ART [2]. Therefore,
this should be the pediatric population to target with an improved
therapeutic vaccine. Such a vaccine would have to show a further
decrease below the set point induced by an anti-retroviral
treatment in order to qualify for a complementary approach.
A longer follow-up of children enrolled in this study would
better clarify the impact of the present vaccine on the long term
viral control. In parallel, larger trials are needed to analyze the
short- and long-term efficacies of therapeutic vaccination in
reducing the rate of virological failures in high risk pediatric
populations.
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